Zacks Investment Research lowered shares of Kadmon (NYSE:KDMN) from a hold rating to a sell rating in a research report report published on Tuesday morning.
According to Zacks, “Kadmon Holdings, Inc. is a biopharmaceutical company. It engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. The company is developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases. Kadmon Holdings, Inc. is headquartered in New York. “
A number of other brokerages have also weighed in on KDMN. Jefferies Group upped their price objective on Kadmon to $16.00 and gave the stock a buy rating in a report on Tuesday, February 13th. Piper Jaffray reaffirmed a positive rating and set a $9.00 price objective (up previously from $7.00) on shares of Kadmon in a report on Tuesday, February 13th. ValuEngine raised Kadmon from a sell rating to a hold rating in a report on Wednesday, May 2nd. Finally, HC Wainwright reaffirmed a buy rating and set a $25.00 price objective on shares of Kadmon in a report on Friday, March 9th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. The company presently has an average rating of Hold and a consensus target price of $11.55.
Kadmon opened at $3.75 on Tuesday, Marketbeat Ratings reports. The company has a market capitalization of $302.57 million, a PE ratio of -2.64 and a beta of 3.97. Kadmon has a 12-month low of $2.05 and a 12-month high of $5.86.
Kadmon (NYSE:KDMN) last announced its quarterly earnings data on Tuesday, May 8th. The company reported ($0.27) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.30) by $0.03. The business had revenue of $0.43 million for the quarter, compared to analyst estimates of $2.67 million. sell-side analysts forecast that Kadmon will post -1.12 EPS for the current year.
A number of institutional investors and hedge funds have recently bought and sold shares of KDMN. Bank of New York Mellon Corp purchased a new stake in Kadmon during the third quarter worth $119,000. Verition Fund Management LLC purchased a new stake in Kadmon during the first quarter worth $139,000. Citadel Advisors LLC boosted its position in Kadmon by 181.3% during the first quarter. Citadel Advisors LLC now owns 49,500 shares of the company’s stock worth $210,000 after purchasing an additional 31,906 shares in the last quarter. BlueCrest Capital Management Ltd purchased a new stake in Kadmon during the fourth quarter worth $241,000. Finally, Wells Fargo & Company MN boosted its position in Kadmon by 23.2% during the third quarter. Wells Fargo & Company MN now owns 73,956 shares of the company’s stock worth $247,000 after purchasing an additional 13,923 shares in the last quarter. Institutional investors own 61.46% of the company’s stock.
Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.
Get a free copy of the Zacks research report on Kadmon (KDMN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.